Evercore ISI analyst Vijay Kumar is adding Boston Scientific (BSX) shares to the firm’s “Tactical Outperform” list heading into Q4 earnings, noting that the stock has underperformed premium growth peers like Stryker (SYK) due to investor fears on a slowdown and its deal that it believes are “overdone.” The firm has an Outperform rating and $112 price target on Boston Scientific shares.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Advances CHORUS IDx: New Imaging Study Targets Smarter Atrial Ablation
- 3 ‘Strong Buy’ Stocks to Buy Today,1/16/2026, According to Top Analysts
- Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst
- 3 ‘Strong Buy’ Stocks with a Perfect 10 Smart Score
- Penumbra downgraded to Hold from Buy at Jefferies